Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy

Journal of Radiation Research

Volumn 56, Issue 4, 2015, Pages 742-749

  Haefner, Matthias F ^a,b   Lang, Kristin ^a,b   Krug, David ^a,b   Koerber, Stefan A ^a,b   Uhlmann, Lorenz ^c   Kieser, Meinhard ^c   Debus, Juergen ^a,b,d   Sterzing, Florian ^a,b,d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Heidelberg Institute of Radiation Oncology (HIRO)   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Definitive chemo radiation; Esophageal cancer; Prognostic factors; Radiotherapy; Toxicity

Indexed keywords

CHEMORADIOTHERAPY; CHEMOTHERAPY; DIAGNOSIS; DISEASES; DOSIMETRY; FACTOR ANALYSIS; MULTIVARIANT ANALYSIS; RADIATION; TOXICITY;

CHEMO RADIATIONS; DEFINITIVE CHEMO-RADIATION; DEFINITIVE RADIOTHERAPY; ESOPHAGEAL CANCER; MEDICAL RECORD; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSTIC FACTORS; PROGRESSION FREE SURVIVAL; RADIOTHERAPY ALONE;

RADIOTHERAPY;

AGE DISTRIBUTION; AGED; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CONFORMAL RADIOTHERAPY; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GERMANY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RADIATION INJURIES; RETROSPECTIVE STUDY; RISK FACTOR; SEX RATIO; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGE DISTRIBUTION; AGED; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84942134912     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1093/jrr/rrv022     Document Type: Conference Paper

References (41)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013;119:1149-58.
3. Lofdahl HE, Lane A, Lu Y, et al. Increased population prevalence of reflux and obesity in the United Kingdom compared with Sweden: a potential explanation for the difference in incidence of esophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2011;23:128-32.
4. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92.
5. Ariga H, Nemoto K, Miyazaki S, et al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2009;75:348-56.
6. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-8.
7. Stahl M, Stuschke M, Lehmann, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-7.
8. Teoh AY, Chiu PW, Yeung WK, et al. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol 2013;24:165-71.
9. Kranzfelder M, Schuster T, Geinitz H, et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 2011;98:768-83.
10. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6.
11. Koppert LB, Lemmens VE, Coebergh JW, et al. Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer. Br J Surg 2012;99:1693-700.
12. Loffeld RJ, Dekkers PE. Experience with oesophageal cancer: a ten-year single centre study reflecting daily practice. ISRN Gastroenterol 2013;2013:205417.
13. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
14. Steyerberg EW, Neville B, Weeks JC, et al. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol 2007;25:2389-96.
15. Crosby TD, Brewster AE, Borley A, et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 2004;90:70-5.
16. Gwynne S, Hurt C, Evans M, et al. Definitive chemoradiation for oesophageal cancer-a standard of care in patients with nonmetastatic oesophageal cancer. Clin Oncol (R Coll Radiol) 2011;23:182-8.
17. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7.
18. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8.
19. Wolf M, Zehentmayr F, Niyazi M, et al. Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol 2010;186:374-81.
20. Hsu FM, Lin CC, Lee JM, et al. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study. J Surg Oncol 2008;98:34-41.
21. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007;17:38-44.
22. Van Hagen P, Hulshof MC, Van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
23. Zhang X, Li M, Meng X, et al. Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2014;9:64.
24. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006: CD002092.
25. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-14.
26. Wang KL, Wu TT, Choi IS, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007;109:658-67.
27. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
28. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013;14:627-37.
29. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006;78:236-44.
30. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combinedmodality therapy for esophageal cancer: high-dose versus standarddose radiation therapy. J Clin Oncol 2002;20:1167-74.
31. Wygoda A, Rutkowski T, Hutnik M, et al. Acute mucosal reactions in patients with head and neck cancer. Three patterns of mucositis observed during radiotherapy. Strahlenther Onkol 2013;189:547-51.
32. Yamashita H, Omori M, Okuma K, et al. Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer. Jpn J Clin Oncol 2014, 44:78-84.
33. Deantonio L, Masini L, Brambilla M, et al. Dysphagia after definitive radiotherapy for head and neck cancer. Correlation of dose-volume parameters of the pharyngeal constrictor muscles. Strahlenther Onkol 2013;189:230-6.
34. Haderlein M, Semrau S, Ott O, et al. Dose-dependent deterioration of swallowing function after induction chemotherapy and definitive chemoradiotherapy for laryngopharyngeal cancer. Strahlenther Onkol 2014;190:192-8.
35. Beukema JC, Van Luijk P, Widder J, et al. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother Oncol 2015;114:85-90.
36. Neuhof D, Neumayer F, Einbeck W, et al. Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Acta Oncol 2005;44:168-73.
37. Wolf MC, Zehentmayr F, Schmidt M, et al. Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre. Radiat Oncol 2012;7:60.
38. Abramyuk A, Appold S, Zophel K, et al. Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy. Strahlenther Onkol 2013;189:197-201.
39. Lambrecht M, Haustermans K. Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiother Oncol 2010;96:339-46.
40. Fakhrian K, Oechsner M, Kampfer S, et al. Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk: planning study in esophageal carcinoma. Strahlenther Onkol 2013;189:293-300.
41. Akutsu Y, Yasuda S, Nagata M, et al. A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol 2012;105:750-5.